caspase9 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
97
Structured Review
Cell Signaling Technology Inc
caspase9
Caspase9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 8888 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/caspase9/Caspase-9+Antibody/pm41934929-132-15-29
Average 97 stars, based on 8888 article reviews
Caspase9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 8888 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/caspase9/Caspase-9+Antibody/pm41934929-132-15-29
Average 97 stars, based on 8888 article reviews
caspase9 - by Bioz Stars,
2026-10
97/100 stars
Images
Related Articles
Blocking Assay:Article Title: Microplastics released from dental materials induce oral inflammatory bone resorption and apoptosis via mitochondrial dysfunction. Article Snippet: .. After blocking, membranes were incubated overnight at 4◦C with primary antibodies against NICD, Bax, Caspase3, Incubation:Article Title: Microplastics released from dental materials induce oral inflammatory bone resorption and apoptosis via mitochondrial dysfunction. Article Snippet: .. After blocking, membranes were incubated overnight at 4◦C with primary antibodies against NICD, Bax, Caspase3, Article Title: NFKBIE as a prognostic biomarker and therapeutic target for GBM: role in Hedgehog signaling activation. Article Snippet: Equal amounts of protein (30 μg) were separated by SDS-PAGE on 10% polyacrylamide gels (Bio-Rad, catalog number 456–1033, USA) and transferred to PVDF membranes (Millipore, catalog number IPVH00010, USA). .. Membranes were blocked with 5% non-fat milk in TBST for 1 h at room temperature, then incubated overnight at 4 °C with primary antibodies against the following proteins: NFKBIE (Abcam, catalog number ab204163, UK), CD133 (Abcam, catalog number ab19898, UK), CD44 (Cell Signaling Technology, catalog number 3560 S, USA), SOX2 (Cell Signaling Technology, catalog number 3579 S, USA), OCT4 (Cell Signaling Technology, catalog number 2840 S, USA), NANOG (Cell Signaling Technology, catalog number 3580 S, USA), Ki67 (Abcam, catalog number ab16667, UK), Caspase3 (Cell Signaling Technology, catalog number 9662 S, USA), Article Title: The postbiotic of hawthorn-probiotic ameliorates constipation by multi-pathway inhibition of PANoptosis in intestinal epithelial cells Article Snippet: Equal protein amounts were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, USA). .. Membranes were blocked with 5% non-fat milk for 1 h, incubated overnight at 4°C with primary antibodies Caspase 1 (1:1000, M025280, Abmart), NLRP3(1:1000, P60622R3, Abmart), GSDMD(1:1000, PU224937 , Abmart), Caspase3(1:500, GTX110543, GeneTex), Caspase9( Article Title: NFKBIE as a prognostic biomarker and therapeutic target for GBM: role in Hedgehog signaling activation Article Snippet: Equal amounts of protein (30 μg) were separated by SDS-PAGE on 10% polyacrylamide gels (Bio-Rad, catalog number 456–1033, USA) and transferred to PVDF membranes (Millipore, catalog number IPVH00010, USA). .. Membranes were blocked with 5% non-fat milk in TBST for 1 h at room temperature, then incubated overnight at 4 °C with primary antibodies against the following proteins: NFKBIE (Abcam, catalog number ab204163, UK), CD133 (Abcam, catalog number ab19898, UK), CD44 (Cell Signaling Technology, catalog number 3560 S, USA), SOX2 (Cell Signaling Technology, catalog number 3579 S, USA), OCT4 (Cell Signaling Technology, catalog number 2840 S, USA), NANOG (Cell Signaling Technology, catalog number 3580 S, USA), Ki67 (Abcam, catalog number ab16667, UK), Caspase3 (Cell Signaling Technology, catalog number 9662 S, USA), Western Blot:Article Title: Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia. Article Snippet: To the Editor, MYD88 mutations (MYD88Mut) are present in several Bcell malignancies, including Waldenström macroglobulinaemia (WM) (95%–97%) and activated Bcell (ABC) subtype of diffuse large Bcell lymphoma (DLBCL) (40%).. MYD88Mut triggers the formation of a ‘Myddosome’, which leads to the sequential activation of IRAK4/IRAK1, JAK2/STAT3 and HCK/BTK prosurvival signalling.1–5 The importance of BTK to MYD88Mut prosurvival signalling supported the development of both covalent and noncovalent BTK inhibitors and the approval of the covalent BTK inhibitors ibrutinib and zanubrutinib for the treatment of symptomatic WM.6,7 Despite the high level of activity of BTK inhibitors in WM, acquired resistance due to the emergence of BTKCys481Ser mutations is common.8 BTKCys481Ser mutations lead to the activation of ERK1/2 MAP kinases, which triggers interleukin (IL)6 and IL10 and propagates paracrinemediated BTKinhibitor resistance.9 Pacritinib is a multikinase inhibitor approved in the United States for the treatment of myelofibrosis.. Pacritinib blocks JAK2/STAT3, IRAK1 and cSRC, a highly homologous kinase to HCK.10,11 Since pacritinib targets multiple kinases implicated in MYD88Mut prosurvival signalling, we explored the repurposing of this U.S. Food and Drug Administration (FDA)approved therapeutic for the treatment of MYD88Mut WM. Control:Article Title: Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia. Article Snippet: To the Editor, MYD88 mutations (MYD88Mut) are present in several Bcell malignancies, including Waldenström macroglobulinaemia (WM) (95%–97%) and activated Bcell (ABC) subtype of diffuse large Bcell lymphoma (DLBCL) (40%).. MYD88Mut triggers the formation of a ‘Myddosome’, which leads to the sequential activation of IRAK4/IRAK1, JAK2/STAT3 and HCK/BTK prosurvival signalling.1–5 The importance of BTK to MYD88Mut prosurvival signalling supported the development of both covalent and noncovalent BTK inhibitors and the approval of the covalent BTK inhibitors ibrutinib and zanubrutinib for the treatment of symptomatic WM.6,7 Despite the high level of activity of BTK inhibitors in WM, acquired resistance due to the emergence of BTKCys481Ser mutations is common.8 BTKCys481Ser mutations lead to the activation of ERK1/2 MAP kinases, which triggers interleukin (IL)6 and IL10 and propagates paracrinemediated BTKinhibitor resistance.9 Pacritinib is a multikinase inhibitor approved in the United States for the treatment of myelofibrosis.. Pacritinib blocks JAK2/STAT3, IRAK1 and cSRC, a highly homologous kinase to HCK.10,11 Since pacritinib targets multiple kinases implicated in MYD88Mut prosurvival signalling, we explored the repurposing of this U.S. Food and Drug Administration (FDA)approved therapeutic for the treatment of MYD88Mut WM. |